Overview

Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia

Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether tifacogin is effective and safe in the treatment of patients with severe community-acquired pneumonia.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Lipoprotein-associated coagulation inhibitor